Related Experiment Video
Updated: Oct 25, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Overcoming Chemotherapy Resistance in SCLC.
Brett H Herzog1, Siddhartha Devarakonda1, Ramaswamy Govindan1
1Division of Oncology, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri; Alvin J Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri.
Small cell lung cancer (SCLC) often recurs after chemotherapy and becomes resistant. Recent research explores SCLC biology, including signaling pathways and metabolism, to overcome this resistance.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis.
- Initial response to platinum-based chemotherapy is common, but relapse with resistance is nearly universal.
Purpose of the Study:
- To review recent findings on SCLC chemotherapy resistance.
- To discuss the clinical implications of new preclinical discoveries in SCLC biology.
Main Methods:
- Literature review of recent advances in SCLC biology.
- Analysis of preclinical data on signaling pathways, transcriptional landscapes, metabolic vulnerabilities, and the tumor microenvironment.
Main Results:
- SCLC recurrence is characterized by widespread therapeutic resistance.
- Altered signaling pathways, transcriptional landscapes, metabolic vulnerabilities, and the tumor microenvironment contribute to resistance.
Conclusions:
- Understanding SCLC biology is crucial for developing strategies to overcome chemotherapy resistance.
- Targeting identified vulnerabilities may improve treatment outcomes for recurrent SCLC.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...